未找到相关数据
A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.
被引：1
作者：
Shitara, Kohei
Yonesaka, Kimio
Denda, Tadamichi
Yamazaki, Kentaro
Moriwaki, Toshikazu
Tsuda, Masahiro
Takano, Toshimi
Okuda, Hiroyuki
Nishina, Tomohiro
Sakai, Kazuko
Nishio, Kazuto
Tokunaga, Shoji
Yamanaka, Takeharu
Boku, Narikazu
Hyodo, Ichinosuke
Muro, Kei
机构：
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3567
引用
收藏
页数：2
相关论文